Literature DB >> 3525403

Lack of effect of nifedipine on counterregulatory mechanisms in essential hypertension.

N E Bruun, H Ibsen, F Nielsen, M D Nielsen, A G Moelbak, O J Hartling.   

Abstract

The influence of long-term nifedipine treatment on body fluid compartments, renal function, the renin-angiotensin system, and the adrenergic system was studied in 18 patients with essential hypertension. A placebo period of 4 weeks was followed by a 6-week dose-titration period. Thereafter, the dose was kept constant for an additional 6 weeks (mean dose, 51 mg/day). As compared with placebo values, diastolic blood pressure decreased approximately 12% during nifedipine treatment. Plasma volume, extracellular fluid volume, and the ratio of plasma to interstitial fluid volume did not change significantly, either in the group as a whole or in a subgroup in which pedal edema developed. Plasma concentrations of epinephrine and norepinephrine increased slightly after 2 weeks of treatment, but they returned to control values after 6 weeks of therapy. Plasma concentrations of renin, angiotensin II, and aldosterone did not change significantly. Glomerular filtration rate and renal clearances of sodium and potassium were unchanged as well. These results indicate that long-term nifedipine treatment does not lead to activation of counterregulatory mechanisms, such as fluid retention or the renin-angiotensin or adrenergic systems. This may well be of importance for the antihypertensive efficacy of nifedipine treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3525403     DOI: 10.1161/01.hyp.8.8.655

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

2.  The haemodynamic effects of long term felodipine therapy in previously untreated essential hypertension.

Authors:  S Capewell; C G Wathen; W J Hannan; A L Muir
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Effects of calcium antagonists on the hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

4.  Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus.

Authors:  B Feldt-Rasmussen; E R Mathiesen; T Deckert; J Giese; N J Christensen; L Bent-Hansen; M D Nielsen
Journal:  Diabetologia       Date:  1987-08       Impact factor: 10.122

5.  Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy.

Authors:  F H Leenen; R J Burns; M G Myers; D Frankel
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

6.  The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group.

Authors:  H Ibsen; B Westberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.